Reach new opportunities in your PROTACs programme(s)
by accessing novel type of linkers.
While efforts are focusing on the protein of interest ligand, and the E3 ubiquitin ligase recruiting ligand, LCC’s compounds present an original alternative to classical linkers and novel options in terms of overall structure/activity of the PROTACs.
We provide semi-flexible linkers that won’t participate into the binding (no supplementary HBD). With a better control of the structural arrangement, new opportunities arise.